Lifebit Biotech Ltd, the precision medicine software company democratising access to biomedical data for governments, healthcare providers and research teams worldwide, has raised a $60 million Series B funding round, led by global investment firm Tiger Global Management. Existing investors Eurazeo, Pentech Ventures, and Beacon Capital also participated.
“Making distributed highly-sensitive biomedical data usable while keeping it secure in-place and combining it with other data has never been possible, until now,” said Dr. Maria Chatzou Dunford, Lifebit CEO. “It’s great to see how excited our investors are to support our mission and first-of-its-kind transformative technology. With this new strategic backing, we will continue to expand our global presence, with a focus on customer success and accelerating the growth of our team.”
Partner at Tiger Global, John Curtius, added, “We are confident that Lifebit’s innovative and industry-leading software solutions, paired with their customer-first approach, will drive rapid global adoption and accelerate breakthroughs in precision medicine.”
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.